Bone morphogenetic proteins and the polycystic ovary syndrome.
| Autor: | van Houten EL; Department of Internal Medicine, Room Ee532, Erasmus MC, P,O Box 2040, Rotterdam, CA 3000, The Netherlands. j.visser@erasmusmc.nl., Laven JS, Louwers YV, McLuskey A, Themmen AP, Visser JA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of ovarian research [J Ovarian Res] 2013 Apr 30; Vol. 6 (1), pp. 32. Date of Electronic Publication: 2013 Apr 30. |
| DOI: | 10.1186/1757-2215-6-32 |
| Abstrakt: | Background: Polycystic Ovary Syndrome (PCOS) is defined by two out of the following three criteria being met: oligo- or anovulation, hyperandrogenism, and polycystic ovaries. Affected women are often obese and insulin resistant. Although the etiology is still unknown, members of the Transforming Growth Factor β (TGFβ) family, including Bone Morphogenetic Proteins (BMPs) and anti-Müllerian hormone (AMH), have been implicated to play a role. In this pilot study we aimed to measure serum BMP levels in PCOS patients. Methods: Twenty patients, fulfilling the definition of PCOS according to the Rotterdam Criteria, were randomly selected. Serum BMP2, -4, -6 and -7 levels were measured using commercially available BMP2, BMP4, BMP6 and BMP7 immunoassays. Results: Serum BMP2, serum BMP4 and serum BMP6 levels were undetectable. Three patients had detectable serum BMP7 levels, albeit at the lower limit of the standard curve. Conclusions: BMP levels were undetectable in almost all patients. This suggests that with the current sensitivity of the BMP assays, measurement of serum BMP levels is not suitable as a diagnostic tool for PCOS. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|